Needham & Company Downgrades Allos Therapeutics (ALTH) to Hold; Modest Increases in FOLOTYN Sales Expected in 2011, as Company Executes Strategy
Go back to Needham & Company Downgrades Allos Therapeutics (ALTH) to Hold; Modest Increases in FOLOTYN Sales Expected in 2011, as Company Executes Strategy| Allos Therapeutics (NASDAQ: ALTH) | Delayed: 1.84 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.84 | 52 Week High | $1.95 | |||
| Open | $166.29 | 52 Week Low | $1.25 | |||
| Day High | $1.84 | P/E | N/A | |||
| Day Low | $1.84 | EPS | $-0.35 | |||
| Volume | 288,441 | |||||
